Replies to post #46836 on Biotech Values

[jellybean]

I've followed this company for several years now and like the potential of their pipeline to expand the use of antibodies in blood borne cancers and autoimmune diseases. The targeted antibodies carrying a payload of toxins is risky, but given the market cap, a freebie.